1,518 Shares in ResMed Inc. (NYSE:RMD) Purchased by EntryPoint Capital LLC

EntryPoint Capital LLC acquired a new stake in ResMed Inc. (NYSE:RMD - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 1,518 shares of the medical equipment provider's stock, valued at approximately $347,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. First Horizon Advisors Inc. increased its stake in ResMed by 285.1% during the 4th quarter. First Horizon Advisors Inc. now owns 593 shares of the medical equipment provider's stock valued at $136,000 after purchasing an additional 439 shares in the last quarter. Peak Financial Advisors LLC bought a new stake in shares of ResMed during the fourth quarter worth about $2,972,000. Principal Financial Group Inc. raised its holdings in shares of ResMed by 2.9% in the 3rd quarter. Principal Financial Group Inc. now owns 186,776 shares of the medical equipment provider's stock worth $45,596,000 after acquiring an additional 5,284 shares during the last quarter. Spire Wealth Management lifted its position in ResMed by 11.3% in the 4th quarter. Spire Wealth Management now owns 10,800 shares of the medical equipment provider's stock valued at $2,470,000 after acquiring an additional 1,100 shares in the last quarter. Finally, Asset Management One Co. Ltd. boosted its stake in ResMed by 2.8% during the 4th quarter. Asset Management One Co. Ltd. now owns 60,489 shares of the medical equipment provider's stock valued at $14,105,000 after purchasing an additional 1,629 shares during the last quarter. Institutional investors own 54.98% of the company's stock.

Analyst Ratings Changes

Several brokerages have recently commented on RMD. Citigroup raised ResMed from a "neutral" rating to a "buy" rating in a research note on Wednesday, March 5th. UBS Group raised ResMed from a "hold" rating to a "strong-buy" rating in a research report on Friday, January 31st. Morgan Stanley initiated coverage on shares of ResMed in a report on Wednesday, March 19th. They set an "overweight" rating and a $280.00 price objective on the stock. The Goldman Sachs Group initiated coverage on shares of ResMed in a research note on Thursday, January 16th. They issued a "buy" rating for the company. Finally, Needham & Company LLC reissued a "hold" rating on shares of ResMed in a research report on Friday, January 31st. One analyst has rated the stock with a sell rating, five have issued a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $249.73.

Remove Ads

Insider Transactions at ResMed

In other news, Director Peter C. Farrell sold 2,000 shares of the business's stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $242.11, for a total value of $484,220.00. Following the sale, the director now owns 77,218 shares of the company's stock, valued at $18,695,249.98. The trade was a 2.52 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Kaushik Ghoshal sold 9,745 shares of the firm's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $239.31, for a total transaction of $2,332,075.95. Following the completion of the transaction, the insider now directly owns 9,725 shares of the company's stock, valued at approximately $2,327,289.75. This trade represents a 50.05 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 38,940 shares of company stock worth $9,164,385. 0.71% of the stock is owned by company insiders.

ResMed Stock Performance

RMD traded up $3.87 during midday trading on Monday, reaching $223.81. The company had a trading volume of 1,086,592 shares, compared to its average volume of 1,003,438. ResMed Inc. has a 12-month low of $172.19 and a 12-month high of $263.05. The business has a 50-day moving average price of $233.37 and a two-hundred day moving average price of $237.83. The stock has a market cap of $32.87 billion, a PE ratio of 26.42, a P/E/G ratio of 1.53 and a beta of 0.74. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.29 and a current ratio of 3.33.

ResMed (NYSE:RMD - Get Free Report) last posted its quarterly earnings data on Thursday, January 30th. The medical equipment provider reported $2.43 EPS for the quarter, beating the consensus estimate of $2.29 by $0.14. ResMed had a return on equity of 26.17% and a net margin of 25.34%. On average, sell-side analysts expect that ResMed Inc. will post 9.47 earnings per share for the current fiscal year.

ResMed Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 13th were paid a dividend of $0.53 per share. The ex-dividend date of this dividend was Thursday, February 13th. This represents a $2.12 annualized dividend and a dividend yield of 0.95%. ResMed's payout ratio is 25.03%.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.